Digital therapeutics (DTx) are changing the healthcare delivery system with evidence-based technologies that improve patient outcomes.Learn About DTx
"After using Freespira I have been able to manage my stress and anxiety, and panic attacks feel like a distant memory. I'm excited to help others live a panic-free life as well."
Talia, United States
“JOGO has reduced my tremors considerably. I am able to sleep better after using JOGO before going to bed.”
Hugh, United States
“Dario has helped me manage my diabetes, because I now know how my body reacts to different foods and meals. Before Dario, my A1c was 9.7. Now its 5.7.”
Richard J., United States
DTA developed the Policymaker & Payor DTx Evaluation Toolkit to provide a common language and process for HCDMs and DTx manufacturers to jointly use throughout DTx product evaluation and implementation processes. It addresses a wide spectrum of HCDM considerations across various settings—ranging from health systems, employers, and private payors, to single-payor government systems—and will continue to be updated to ensure ongoing relevance in this quickly evolving ecosystem.Learn More about the DTx Evaluation Toolkit
The Digital Therapeutics Alliance is a global non-profit trade association of industry leaders and stakeholders engaged in the advancement of evidence-driven digital therapeutics.
DTA works to broaden the understanding, adoption, and integration of clinically evaluated digital therapeutics into healthcare through education, advocacy, and cross-industry collaboration. DTA maintains an international industry presence and is proud to work with members from 17 countries spread across five continents.Join DTA's Global Efforts
Member organizations play a critical role in transforming healthcare by delivering an impressive array of therapeutic interventions that improve clinical and health economic outcomes. Learn more about DTA and member company contributions.